GlassScriptPhysician profile
Susan R Bailey
NPI 1396722583
$4,477.10
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $452 · 2021: $148 · 2022: $189 · 2023: $1,001 · 2024: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,763 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,763.31 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $638.86 | 2019-2024 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $503.99 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $446.68 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $439.25 | 2019-2024 | Xembify |
| Blueprint Medicines Corporation | $372.53 | 2023-2024 | Ayvakit |
| Novartis Pharmaceuticals Corporation | $299.38 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $290.56 | 2020-2024 | Takhzyro |
| Glaxosmithkline, LLC. | $249.49 | 2020-2024 | Nucala, Trelegy Ellipta |
| Csl Behring | $196.57 | 2019-2024 | Hizentra |
| Genentech USA, INC. | $179.16 | 2019-2024 | Xolair |
| Pfizer INC. | $159.29 | 2019-2024 | |
| Covis Pharma Gmbh | $131.47 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Pharming Healthcare, INC. | $77.54 | 2019-2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $70.81 | 2019-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $70.80 | 2019-2024 | Tezspire |
| Shire North American Group INC | $63.14 | 2019 | |
| Optinose US, INC. | $47.77 | 2023-2024 | |
| Incyte Corporation | $44.03 | 2023 | Opzelura |
| Alk-Abello, INC | $43.52 | 2020-2023 | Grastek, Ragwitek, Odactra |
| Biocryst US Sales Co., LLC | $39.97 | 2024 | Orladeyo |
| Kaleo, INC. | $17.46 | 2023 | Auvi-Q |
| Hikma Pharmaceuticals USA | $14.84 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.